• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. An astrophysically-relevant mechanism for amino acid enantiomer enrichment
  Stephen P. Fletcher,Richard B. C. Jagt,Ben L. Feringa Chem. Commun., 2007, 2578-2580
• 3. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 4. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 5. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzopyrazoles Indazoles

Recent Advances in the Study of 4-Fluoro-3-iodo-7-nitro-indazole (CAS: 1000343-07-6)

The compound 4-Fluoro-3-iodo-7-nitro-indazole (CAS: 1000343-07-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its synthesis, biological activity, and potential applications in drug discovery.

Recent studies have highlighted the role of 4-Fluoro-3-iodo-7-nitro-indazole as a versatile scaffold for the development of kinase inhibitors. Its structural features, including the fluorine and iodine substituents, make it an attractive candidate for modulating protein-protein interactions and enzyme activity. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy in inhibiting specific kinases involved in cancer cell proliferation, with IC50 values in the nanomolar range.

In addition to its kinase inhibitory properties, 4-Fluoro-3-iodo-7-nitro-indazole has shown promise in the field of neurodegenerative diseases. Research conducted at the University of Cambridge revealed its potential as a modulator of tau protein aggregation, a key pathological feature of Alzheimer's disease. The compound's ability to cross the blood-brain barrier further enhances its therapeutic potential for central nervous system disorders.

The synthetic pathways for 4-Fluoro-3-iodo-7-nitro-indazole have also been optimized in recent years. A 2022 publication in Organic Process Research & Development described a novel, scalable synthesis route that improves yield and purity while reducing environmental impact. This advancement is particularly significant for potential industrial-scale production of the compound and its derivatives.

Structural-activity relationship (SAR) studies have provided valuable insights into the pharmacophore of 4-Fluoro-3-iodo-7-nitro-indazole. Researchers have identified that the nitro group at position 7 is crucial for maintaining biological activity, while the iodine at position 3 allows for further derivatization through cross-coupling reactions. These findings have opened new avenues for the development of more potent and selective analogs.

From a safety and toxicology perspective, preliminary in vitro and in vivo studies suggest that 4-Fluoro-3-iodo-7-nitro-indazole has a favorable pharmacokinetic profile. However, further investigation is needed to fully assess its potential off-target effects and long-term safety. Current research is focusing on optimizing its drug-like properties while maintaining its biological activity.

The compound has also found applications in chemical biology as a tool compound for studying cellular signaling pathways. Its ability to selectively label certain proteins makes it valuable for proteomics studies and target identification. This dual functionality as both a potential therapeutic agent and a research tool underscores its importance in modern drug discovery.

Looking forward, the research community anticipates that 4-Fluoro-3-iodo-7-nitro-indazole and its derivatives will play an increasingly important role in the development of targeted therapies for various diseases. Ongoing clinical trials and structure optimization studies are expected to further elucidate its full therapeutic potential and possible applications in personalized medicine.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)